The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 16, 2024

Filed:

Oct. 05, 2022
Applicant:

Christiana Care Gene Editing Institute, Inc., Wilmington, DE (US);

Inventors:

Eric B. Kmiec, Middletown, DE (US);

Pawel Bialk, Wilmington, DE (US);

Kelly H. Banas, Bear, DE (US);

Assignee:
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C12N 15/11 (2006.01); A61K 31/7088 (2006.01); A61K 38/00 (2006.01); A61K 38/46 (2006.01); A61K 48/00 (2006.01); A61P 35/00 (2006.01); C12N 9/22 (2006.01); C12N 15/113 (2010.01); C12N 15/85 (2006.01); C12N 15/90 (2006.01);
U.S. Cl.
CPC ...
C12N 15/11 (2013.01); A61K 48/005 (2013.01); A61P 35/00 (2018.01); C12N 9/22 (2013.01); C12N 15/85 (2013.01); A61K 38/00 (2013.01); C12N 2310/20 (2017.05); C12N 2800/80 (2013.01);
Abstract

The disclosure provides a guide RNA (gRNA) comprising a DNA-binding domain and a Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)-associated endonuclease protein-binding domain, wherein the DNA-binding domain is complementary to a target domain from a variant NRF2 gene found in a cancer cell but not in a non-cancerous cell. The disclosure also provides nucleic acid sequence encoding the gRNA. The disclosure further provides a method of treating cancer in a subject comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising a Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)-associated endonuclease and a guide RNA that is complementary to a target domain from a variant NRF2 gene in the subject. Methods of treating cancer comprising administering a pharmaceutical composition comprising: a DNA sequence encoding a guide RNA that is complementary to a target domain from a variant NRF2 gene in the subject; and a nucleic acid sequence encoding a Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)-associated endonuclease, are also provided.


Find Patent Forward Citations

Loading…